Multifunctional drug delivery systems combined with trametinib reverses multidrug resistance in ovarian and colorectal cancer (collection)

Multifunctional drug delivery systems combined with trametinib reverses multidrug resistance in ovarian and colorectal cancer

DOI:10.4121/a1f3608f-d660-4b5d-a4a0-86babb90538b.v1

The DOI displayed above is for this specific version of this collection, which is currently the latest. Newer versions may be published in the future. For a link that will always point to the latest version, please use
DOI: 10.4121/a1f3608f-d660-4b5d-a4a0-86babb90538b

Datacite citation style

Zhu, Junqiao (2025): Multifunctional drug delivery systems combined with trametinib reverses multidrug resistance in ovarian and colorectal cancer. Version 1. 4TU.ResearchData. collection. https://doi.org/10.4121/a1f3608f-d660-4b5d-a4a0-86babb90538b.v1

Other citation styles (APA, Harvard, MLA, Vancouver, Chicago, IEEE) available at Datacite

Collection

Keywords

drug delivery system endocytic pathway multidrug resistance P-gp inhibitor trametinib

by Junqiao Zhu

The overexpression of P-glycoprotein (P-gp) on cell membrane is one of the most important reasons for multidrug resistance (MDR) in cancer. Multifunctional drug delivery systems could only reverse MDR to some extent through bypassing the drug pump mediated by P-gp. It has been reported that trametinib could selectively inhibit the function of P-gp. However, there are no reports on the use of trametinib combined with drug delivery systems to reverse MDR at present. In this study, we constructed two types of drug delivery systems (H-F-DOX NPs and H-F-Tat-DOX NPs) based heparin as backbone with folate and cell penetrating peptide Tat for achieving active targeting. The results indicate that trametinib could enhance the cellular uptake of multifunctional drug delivery systems on drug-resistant cancer cells by specifically inhibiting the function of P-gp, change the endocytic pathway of drug delivery systems and release doxorubicin into the nucleus to kill drug-resistant cells, paving a new way to reverse MDR in ovarian and colorectal cancer.